interesting legalities. Given that 2591 has already been granted FDA orphan designation for PW, wouldn't that null the anti competetive clauses for that condition? suppose acadia came out and said we are targeting PW with trof, and 6 months later neuren lodged a ophan application for 2591, then sure - but the other way around?
tried to read the licencing agreement but ran out of coffee
Ann: Investor Presentation, 14 March 2023, page-63
-
- There are more pages in this discussion • 83 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.45 |
Change
-0.070(0.34%) |
Mkt cap ! $2.613B | |||
| Open | High | Low | Value | Volume |
| $20.60 | $20.77 | $20.32 | $3.866M | 188.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 237 | $20.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.49 | 1026 | 2 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |